Pharmaceuticals
* Please select month and year together
Intravenous Infusions PLC reports financial results for the year ended 31 December 2025. Key metrics: Revenue: GHS 9.30 million (2024: GHS 24.94 million) Net Loss: GHS 4.63 million (2024: GHS 0.64 million loss) Loss Per Share: GHS 0.0169 (2024: GHS 0.0023 loss) Dividend Paid: GHS 150,000 The company secured a […]
Document type: Annual Reports
Published: Apr 24, 2026
Year: 2025
Period:
Pharmaceuticals | Ghana
Neimeth International Pharmaceuticals PLC reports financial results for the year ended 31 December 2025. Key financial metrics: Revenue: ₦7.4 billion, an increase of 64% from ₦4.5 billion in 2024. Profit After Tax: ₦976.4 million, compared to a loss of ₦885.3 million in 2024. Earnings Per Share: 23 kobo, compared to […]
Document type: Annual Reports
Published: Apr 7, 2026
Year: 2025
Period:
Pharmaceuticals | Nigeria
May and Baker Nigeria PLC reports financial results for the year ended 31 December 2025. FY 2025 Financial Highlights: Revenue: ₦38.26 billion, a 36% increase year-on-year. Profit After Tax: ₦4.44 billion, a 173.7% increase year-on-year. Basic Earnings Per Share: 257.15 Kobo, compared to 93.96 Kobo in 2024. Gross Profit Margin: […]
Document type: Annual Reports
Published: Apr 7, 2026
Year: 2025
Period:
Pharmaceuticals | Nigeria
Juli PLC reports for the year ended 31 December 2025: Revenue was ₦479.87 million, consistent with the prior year. Net loss increased to (₦55.81 million) from (₦17.48 million) due to higher administrative expenses. The shareholders deficit was (₦490.60 million), an improvement from (₦627.86 million) in 2024, as total liabilities decreased. […]
Document type: Interim Reports
Published: Apr 7, 2026
Year: 2025
Period: Q4
Pharmaceuticals | Nigeria
MeCure Industries Limited: Financial results for the year ended 31 December 2019. Revenue: N15.81 billion, a 4.2% increase year-on-year. Operating Profit: N2.14 billion. Profit for the Year: N303.91 million. Total Assets: N13.69 billion. Capital expenditure in property, plant, and equipment was N2.79 billion. Basic Earnings Per Share: N15.20.
Document type: Annual Reports
Published: Mar 31, 2020
Year: 2019
Period:
Pharmaceuticals | Nigeria
For the financial year ended 31 December 2020, MeCure Industries Limited recorded revenue of N17.42 billion, a 10.1% increase year-on-year. Profit for the year was N658.5 million, a 116.7% increase from 2019. Basic Earnings Per Share grew to N32.92 from N15.20. Capital expenditure on property, plant, and equipment was N3.15 […]
Document type: Annual Reports
Published: Mar 31, 2021
Year: 2020
Period:
Pharmaceuticals | Nigeria
MeCure Industries Limited financial results for the year ended 31 December 2021. Key Metrics: Revenue: N20.70 billion, up 18.8% year-on-year. Operating Profit: N3.54 billion, up 47.6% year-on-year. Profit for the Year: N672.7 million. Earnings Per Share: N33.64. Operating Profit Margin: 17.1%, from 13.7% in 2020. The company made additions of […]
Document type: Annual Reports
Published: Mar 31, 2022
Year: 2021
Period:
Pharmaceuticals | Nigeria
Mecure Industries Limited reports financial results for the year ended 31 December 2018. Revenue increased 36.3% to ₦15.17 billion. Profit after tax was ₦933.5 million, with earnings per share at ₦46.67. Total assets grew to ₦12.74 billion from ₦8.93 billion in the prior year. The company capitalized ₦1.46 billion in […]
Document type: Annual Reports
Published: Mar 29, 2019
Year: 2018
Period:
Pharmaceuticals | Nigeria
MeCure Industries Plc: Nigerian pharmaceutical manufacturer & distributor with strong 2025 growth. Revenue +69%, Profit +177%. Invested in cancer care.
Pharmaceuticals | Nigeria
MeCure Industries Plc reports financial results for the year ended 31 December 2025. Key metrics: Revenue: ₦77.69 billion, an increase of 69%. Operating Profit: ₦16.43 billion, an increase of 98%. Profit for the Year: ₦6.46 billion, an increase of 177%. Earnings Per Share: ₦1.62, from ₦0.58 in 2024. The Board […]
Document type: Annual Reports
Published: Mar 2, 2026
Year: 2025
Period:
Pharmaceuticals | Nigeria
For the nine months to 31 December 2025, Africure Pharmaceuticals Ltd. reported revenue of $18.6M, a 24% decrease from the prior period, attributed to a reduction in government business. Core retail and base business revenue improved by $5.35M. Gross margin increased to 42% from 35%. EBITDA was $2.82M. The company […]
Document type: Interim Reports
Published: Feb 17, 2026
Year: 2026
Period: Q3
Pharmaceuticals | Mauritius
Feb 5, 2026 –
Qcil is pleased to announce an interim dividend for the financial year ending 31 March 2026. The Board of Directors, at the meeting held on 4 February 2026, resolved to declare an interim dividend of UGX 6.0 per share, payable on or before 5 March 2026 to shareholders whose names […]
Corporate announcement, Dividends | Uganda
THE INVESTOR MAILING LIST
The investor mailing list (IML) is an investor relations newsletter focused on African stock markets. The IML has all the essential share trading updates, financial documents, news and corporate announcements. The newsletter currently covers 11 African stock markets and is free.